A Review of Molecular and Genetic Diagnostics of Myeloid Malignancies with Emphasis on Diagnostics in Bosnia and Herzegovina

Authors

  • Amina Kurtovic-Kozaric Department of Clinical Pathology, Cytology and Human Genetics, Clinical Center of the University of Sarajevo, Sarajevo ; Faculty of Science, University of Sarajevo, Sarajevo ; Department of Genetics and Bioengineering, International Burch University, Sarajevo
  • Erna Islamagic Faculty of Science, University of Sarajevo, Sarajevo
  • Adna Asic Department of Genetics and Bioengineering, International Burch University, Sarajevo
  • Lejla Mehinovic-Cavcic Faculty of Science, University of Sarajevo, Sarajevo
  • Larisa Besic Department of Genetics and Bioengineering, International Burch University, Sarajevo
  • Hana Sahinbegovic Faculty of Medicine, University of Ostrava, Ostrava ; Faculty of Science, University of Ostrava, Ostrava
  • Hana Komic TIMM Laboratory, Sahlgrenska Center for Cancer Research, University of Gothenburg, Gothenburg
  • Sabira Kurtovic Hematology Clinic, Clinical Center of the University of Sarajevo, Sarajevo
  • Lejla Burazerovic Hematology Clinic, Clinical Center of the University of Sarajevo, Sarajevo

DOI:

https://doi.org/10.5644/ama2006-124.334

Keywords:

Myeloid Neoplasms, Molecular Diagnostics, Myeloproliferative Neoplasms, Myelodysplastic Syndrome, Acute Myeloid Leukemia

Abstract

Here we describe the major genetic and genomic aberrations found in myeloid malignancies and how those markers are used in patients’ diagnosis, prognosis, and targeted treatment. In Bosnia and Herzegovina, cytogenetic and molecular diagnostics for myeloid malignancies have been established and continually improved since 2005. We report the current state of available diagnostic tools for myeloid malignancies in Bosnia and Herzegovina. Myeloid malignancies are a heterogeneous group of clonal blood diseases characterized by defects in hematopoietic stem cells and myeloid progenitors that lead to abnormal proliferation, differentiation, localization, and self-renewal. Most common myeloid malignancies include myeloproliferative neoplasms (MPNs), myelodysplastic syndrome (MDS), and acute myeloid leukemia (AML). Molecular diagnostics of myeloid malignancies have significantly expanded in the last decade with new genetic and genomic markers for diagnosis, prognosis, and treatment.

Conclusion. In the last decade, several new genomic markers important for patient diagnosis, prognosis, and therapy have been discovered that need to be implemented in routine molecular diagnostics not only in developed nations but also in developing nations such as Bosnia and Herzegovina.

Downloads

Download data is not yet available.

Downloads

Published

2021-05-26

How to Cite

Kurtovic-Kozaric, A., Islamagic, E., Asic, A., Mehinovic-Cavcic, L., Besic, L., Sahinbegovic, H., Komic, H., Kurtovic, S., & Burazerovic, L. (2021). A Review of Molecular and Genetic Diagnostics of Myeloid Malignancies with Emphasis on Diagnostics in Bosnia and Herzegovina. Acta Medica Academica, 50(1), 175–196. https://doi.org/10.5644/ama2006-124.334

Issue

Vol. 50 No. 1 (2021): Special Issue: Diagnostic and Molecular Pathology Advances

Section

Clinical Science

Most read articles by the same author(s)